newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference

ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indication